* Voyager Therapeutics Inc VYGR.OQ reported quarterly
adjusted
earnings of $1.25 per share for the quarter ended in December,
higher than the same quarter last year, when the company
reported EPS of -61 cents. The mean expectation of
seven analysts for the quarter was for a loss of 29 cents per
share. Wall Street expected results to range from -62 cents
to $1.33 per share.
* Revenue rose 5,910.4% to $90.06 million from a year ago;
analysts expected $20.64 million.
* Voyager Therapeutics Inc's reported EPS for the quarter
was
$1.25.
* The company reported quarterly net income of $56.4
million.
* Voyager Therapeutics Inc shares had risen by 5.6% this
quarter.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 50.7%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Voyager
Therapeutics Inc is $16.00
This summary was machine generated from LSEG data February 28 at
11:14 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Dec. 31 2023 -0.29 1.25 Beat
Sep. 30 2023 -0.58 -0.59 Missed
Jun. 30 2023 -0.57 -0.51 Beat
Mar. 31 2023 0.77 2.94 Beat